MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, SUPN made $207,705K in revenue. -$2,293K in net income. Net profit margin of -1.10%.

Income Overview

Revenue
$207,705K
Net Income
-$2,293K
Net Profit Margin
-1.10%
EPS
-$0.04
Unit: Thousand (K) dollars
Revenue Breakdown
    • Qelbree
    • GOCOVRI
    • Royalty License And Other Revenu...
    • Others

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenues
207,705 211,572 192,103 165,453
Cost of revenues
23,391 23,007 18,965 16,827
Research and development
39,438 27,827 29,366 22,115
Selling, general and administrative
125,173 122,390 179,678 93,551
Amortization of intangible assets
25,644 24,526 24,325 20,819
Intangible asset impairment charges
-0 --
Contingent consideration loss
2,391 17,759 0 0
Total costs and expenses
216,037 215,509 252,334 153,312
Operating loss
-8,332 -3,937 -60,231 12,141
Interest and other income, net
2,382 2,023 2,277 4,528
Interest expense
-0 --
Total other income (expense), net
2,382 2,023 2,277 4,528
Loss before income taxes
-5,950 -1,914 -57,954 16,669
Income tax expense (benefit)
-3,657 2,191 -12,837 -5,830
Net loss
-2,293 -4,105 -45,117 22,499
Basic EPS
-0.04 -0.072 -0.8 0.4
Diluted EPS
-0.04 -0.072 -0.8 0.4
Basic Average Shares
57,647,548 57,362,340 56,552,741 56,024,771
Diluted Average Shares
57,647,548 56,743,922 56,552,741 56,643,189
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$2,293K (80.61%↑ Y/Y)Income tax expense(benefit)-$3,657K (-160.99%↓ Y/Y)Interest and otherincome, net$2,382K (-46.17%↓ Y/Y)Qelbree$77,843K (20.23%↑ Y/Y)GOCOVRI$35,240K (14.83%↑ Y/Y)Trokendi Xr$9,479K (-25.95%↓ Y/Y)ONAPGO$8,375K APOKYN$7,728K (-48.40%↓ Y/Y)Oxtellar XR$7,422K (-27.22%↓ Y/Y)Manufactured Product Other$4,666K (-45.61%↓ Y/Y)Loss before incometaxes-$5,950K (-2.04%↓ Y/Y)Total other income(expense), net$2,382K (-46.17%↓ Y/Y)Product$150,753K (6.17%↑ Y/Y)Royalty License AndOther Revenue$29,309K (274.03%↑ Y/Y)Collaboration Revenue$27,643K Operating loss-$8,332K (18.76%↑ Y/Y)Total revenues$207,705K (38.63%↑ Y/Y)Total costs andexpenses$216,037K (34.96%↑ Y/Y)Selling, general andadministrative$125,173K (39.17%↑ Y/Y)Research and development$39,438K (46.46%↑ Y/Y)Amortization of intangibleassets$25,644K (29.61%↑ Y/Y)Cost of revenues$23,391K (48.39%↑ Y/Y)Contingent considerationloss$2,391K (-68.79%↓ Y/Y)

SUPERNUS PHARMACEUTICALS, INC. (SUPN)

SUPERNUS PHARMACEUTICALS, INC. (SUPN)